Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | WRN | Q14191 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728346 | 1.00 | GRM4 (0.43) | GRM4RAB9ABLMWRNEGFR | |
| SCHEMBL14169142 | 0.84 | GRM4 (0.43) | GRM4RAB9ABLMWRNEGFR | |
| SCHEMBL4728379 | 0.81 | MEN1 (0.51) | RAB9AALDH1A1 | |
| SCHEMBL4728377 | 0.81 | MEN1 (0.51) | RAB9AALDH1A1 | |
| SCHEMBL4728348 | 0.78 | IDO1 (0.48) | — | |
| SCHEMBL4725734 | 0.78 | ALDH1A1 (0.48) | GRM4RAB9ABLMWRNEGFR | |
| SCHEMBL4725732 | 0.78 | ALDH1A1 (0.48) | GRM4RAB9ABLMWRNEGFR | |
| SCHEMBL4729476 | 0.77 | ALDH1A1 (0.49) | GRM4RAB9AKCNK3KCNK9ALDH1A1 | |
| SCHEMBL4729477 | 0.77 | ALDH1A1 (0.49) | GRM4RAB9AKCNK3KCNK9ALDH1A1 | |
| SCHEMBL4727448 | 0.75 | GRM4 (0.48) | GRM4BLMWRNEGFRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008036652-A2 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | GRM4 489/4885RAB9A 3383/4885BLM 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.